succinimide has been researched along with thalidomide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bär, K; Boichenko, I; Deiss, S; Hartmann, MD; Hernandez Alvarez, B | 1 |
| Bär, K; Giannis, A; Hartmann, MD; Heim, C; Hernandez Alvarez, B; Mousavizadeh, F; Pliatsika, D | 1 |
| Hartmann, MD; Heim, C; Hernandez Alvarez, B; Maiwald, S | 1 |
3 other study(ies) available for succinimide and thalidomide
| Article | Year |
|---|---|
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Caenorhabditis elegans Proteins; Drug Design; Fluorescence Resonance Energy Transfer; High-Throughput Screening Assays; Humans; Ligands; Magnetospirillum; Models, Molecular; Peptide Hydrolases; Protein Binding; Small Molecule Libraries; Teratogens; Ubiquitin-Protein Ligases | 2016 |
De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.
Topics: Adaptor Proteins, Signal Transducing; Cell Line; Drug Design; Humans; Hydrolysis; Ikaros Transcription Factor; Molecular Docking Simulation; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2019 |
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
Topics: | 2021 |